TNFRSF17 and plasma cell myeloma: Recently, the FDA approved several CAR T cell therapeutic regimens, such as Lisocabtagene maraleucel, which targets CD19 antigen and is used to treat relapsed or refractory large B-cell lymphoma; and Idecabtagene vicleucel and Ciltacabtagene autoleucel both of which target B cell maturation antigen (BCMA) and are used against relapsed or refractory multiple myeloma [135].